Review



foundationone heme  (Foundation Medicine Inc)


Bioz Verified Symbol Foundation Medicine Inc is a verified supplier
Bioz Manufacturer Symbol Foundation Medicine Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Foundation Medicine Inc foundationone heme
    Foundationone Heme, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 95/100, based on 398 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foundationone+heme+assay/FoundationOne+Heme/custom%40foundationone-heme%4010%2E1016%2Fj%2Eesmorw%2E2026%2E100724
    Average 95 stars, based on 398 article reviews
    foundationone heme - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    Next-Generation Sequencing:

    Article Title: Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies.
    Article Snippet: .. Tumor tissue profiling by massively parallel NGS of 406 genes and select introns of 31 genes involved in rearrangements as well as RNA sequencing (cDNA) of 265 commonly rearranged genes fusions were performed using the FoundationOne Heme assay (Foundation Medicine, Cambridge, MA, USA) as described previously.26,27 TMB was determined on 1.2 megabases of DNA sequence, excluding germline A-R Jeong, AH Trando et al. journals.sagepub.com/home/tam 3 and driver alterations from the calculation.28 Microsatellite instability (MSI) was determined by examining homopolymer repeat regions.29 PD-L1 scores of the tumor were classified as high (⩾50%), low (1–49%), and negative (<1%). .. PD-L1 tumor proportion score (TPS) was determined by immunohistochemistry (IHC) performed at Foundation Medicine.

    Article Title: An SS18::NEDD4 cutaneous spindled and epithelioid sarcoma: An hitherto unclassified cutaneous sarcoma, resembling epithelioid sarcoma with aggressive clinical behavior
    Article Snippet: .. NGS was performed using the FoundationOne Heme assay (Foundation Medicine, Inc. Cambridge, MA). ..

    Article Title: Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies
    Article Snippet: .. Tumor tissue profiling by massively parallel NGS of 406 genes and select introns of 31 genes involved in rearrangements as well as RNA sequencing (cDNA) of 265 commonly rearranged genes fusions were performed using the FoundationOne Heme assay (Foundation Medicine, Cambridge, MA, USA) as described previously., TMB was determined on 1.2 megabases of DNA sequence, excluding germline and driver alterations from the calculation. ..

    Article Title: Optimal Molecular Methods in Detecting p190 BCR-ABL Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature
    Article Snippet: .. Due to this discrepancy, peripheral blood was sent for testing on the FoundationOne Heme assay (Foundation Medicine, Cambridge MA), a next generation sequencing (NGS) based assay. ..

    RNA Sequencing:

    Article Title: Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies.
    Article Snippet: .. Tumor tissue profiling by massively parallel NGS of 406 genes and select introns of 31 genes involved in rearrangements as well as RNA sequencing (cDNA) of 265 commonly rearranged genes fusions were performed using the FoundationOne Heme assay (Foundation Medicine, Cambridge, MA, USA) as described previously.26,27 TMB was determined on 1.2 megabases of DNA sequence, excluding germline A-R Jeong, AH Trando et al. journals.sagepub.com/home/tam 3 and driver alterations from the calculation.28 Microsatellite instability (MSI) was determined by examining homopolymer repeat regions.29 PD-L1 scores of the tumor were classified as high (⩾50%), low (1–49%), and negative (<1%). .. PD-L1 tumor proportion score (TPS) was determined by immunohistochemistry (IHC) performed at Foundation Medicine.

    Article Title: Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies
    Article Snippet: .. Tumor tissue profiling by massively parallel NGS of 406 genes and select introns of 31 genes involved in rearrangements as well as RNA sequencing (cDNA) of 265 commonly rearranged genes fusions were performed using the FoundationOne Heme assay (Foundation Medicine, Cambridge, MA, USA) as described previously., TMB was determined on 1.2 megabases of DNA sequence, excluding germline and driver alterations from the calculation. ..

    Article Title: Optimal Molecular Methods in Detecting p190 BCR-ABL Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature
    Article Snippet: .. FoundationOne Heme Assay (Foundation Medicine, Cambridge MA) uses hybridization capture applied to ≥50 nanograms of extracted DNA or RNA for 405 cancer related genes and select intronic regions from 31 genes (FoundationOne Heme DNA only, n = 405); targeted RNA-seq for rearrangement analysis was performed for 265 genes that are frequently rearranged in cancer. .. Sequencing of captured libraries was performed using an Illumina HiSeq 2500 to a median exon coverage depth of >250x, and resultant sequences were analyzed for base substitutions, insertions, deletions, copy number alterations (focal amplifications and homozygous deletions), and select gene fusions, as previously described.

    Sequencing:

    Article Title: Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies.
    Article Snippet: .. Tumor tissue profiling by massively parallel NGS of 406 genes and select introns of 31 genes involved in rearrangements as well as RNA sequencing (cDNA) of 265 commonly rearranged genes fusions were performed using the FoundationOne Heme assay (Foundation Medicine, Cambridge, MA, USA) as described previously.26,27 TMB was determined on 1.2 megabases of DNA sequence, excluding germline A-R Jeong, AH Trando et al. journals.sagepub.com/home/tam 3 and driver alterations from the calculation.28 Microsatellite instability (MSI) was determined by examining homopolymer repeat regions.29 PD-L1 scores of the tumor were classified as high (⩾50%), low (1–49%), and negative (<1%). .. PD-L1 tumor proportion score (TPS) was determined by immunohistochemistry (IHC) performed at Foundation Medicine.

    Article Title: Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies
    Article Snippet: .. Tumor tissue profiling by massively parallel NGS of 406 genes and select introns of 31 genes involved in rearrangements as well as RNA sequencing (cDNA) of 265 commonly rearranged genes fusions were performed using the FoundationOne Heme assay (Foundation Medicine, Cambridge, MA, USA) as described previously., TMB was determined on 1.2 megabases of DNA sequence, excluding germline and driver alterations from the calculation. ..

    Hybridization:

    Article Title: Optimal Molecular Methods in Detecting p190 BCR-ABL Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature
    Article Snippet: .. FoundationOne Heme Assay (Foundation Medicine, Cambridge MA) uses hybridization capture applied to ≥50 nanograms of extracted DNA or RNA for 405 cancer related genes and select intronic regions from 31 genes (FoundationOne Heme DNA only, n = 405); targeted RNA-seq for rearrangement analysis was performed for 265 genes that are frequently rearranged in cancer. .. Sequencing of captured libraries was performed using an Illumina HiSeq 2500 to a median exon coverage depth of >250x, and resultant sequences were analyzed for base substitutions, insertions, deletions, copy number alterations (focal amplifications and homozygous deletions), and select gene fusions, as previously described.



    Similar Products

    foundationone heme  (Foundation Medicine Inc)
    95
    Foundation Medicine Inc foundationone heme
    Foundationone Heme, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foundationone+heme+assay/FoundationOne+Heme/custom%40foundationone-heme%4010%2E1016%2Fj%2Eesmorw%2E2026%2E100724
    Average 95 stars, based on 1 article reviews
    foundationone heme - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier

    Image Search Results